Navigation Links
Neurocrine Biosciences to Present at the Thomas Weisel Partners Healthcare Conference
Date:9/2/2009

SAN DIEGO, Sept. 2 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Thomas Weisel Partners Healthcare Conference in Boston.

The live presentation takes place Wednesday, September 9, 2009 at 9:45 a.m. Eastern Time (ET)/6:45 a.m. Pacific Time (PT). The presentation will be simultaneously webcast and may be accessed on the Company's website at http://www.neurocrine.com.

If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrine Biosciences at (858) 617-7600. Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the conclusion of the live event and will be archived on the website for two weeks.

About Neurocrine

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH), irritable bowel syndrome (IBS) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2009 Financial Results
3. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2008 Results
4. Webcast Alert: Neurocrine Announces 1Q08 Financial Results
5. Neurocrine Announces Closing of $109 Million Sale and Leaseback Agreement for its Real Estate Assets
6. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
7. Cell Biosciences Launches Unique Protein Phosphorylation Assay Service
8. Sartorius Stedim Biotech Partners With Cell Culture Media Specialist SAFC Biosciences(R) to Provide World-Class Fluid Management and Liquid/Powder System Solutions
9. Catalyst Biosciences Announces Agreement With MedImmune to Discover and Develop Engineered Protease Therapeutics
10. Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products
11. Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data at ADA 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... ... to announce the ATA 2017 President’s Awards recipients, comprised of organizations and ... healthcare delivery. , The ATA 2017 President’s Awards recognize individuals and ...
(Date:4/26/2017)... ... April 26, 2017 , ... The National ... upon National Registry of Emergency Medical Technicians and welcomes this organization ... Dr. Jan G. West, Ph.D. , CEO & Organizational Psychologist at NBRI. ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... a unique website ( CRISPRCas.pioneer.com ) that demonstrates how this advanced plant breeding ... more and better food, with fewer resources. It highlights the business’ principles, research ...
(Date:4/25/2017)... ... April 25, 2017 , ... Bellus Medical, a leader in ... a new class of photodynamic cosmetics (PDC). , Allumera® is the first PDC ... signs of aging, and minimize the appearance of pores – all with minimal ...
(Date:4/25/2017)... ... April 25, 2017 , ... A stressful work environment can hurt the physical ... productivity and performance in the workplace. The goal of Clearview Resolution Services has always ... of April, Clearview Resolution Services will be shutting down the office early on Fridays. ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
(Date:4/19/2017)... , April 19, 2017  SARES•REGIS Group ... it is developing at Conejo Spectrum Business Park ... to Atara Biotherapeutics, Inc. , a biopharmaceutical ... and life-threatening diseases that have been underserved by ... T-cell therapies for cancer, autoimmune and infectious disease. ...
(Date:4/18/2017)... 18, 2017 Research and Markets has announced ... report to their offering. ... global arthroscopy devices market to grow at a CAGR of 6.35% ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
Breaking Medicine Technology: